ASH 2021 | Transplant outcomes of AML/HR-MDS patients treated with sabatolimab plus HMA
Andrew M. Brunner, MD, Massachusetts General Hospital, Boston, MA, discusses a study which analyzed the safety and efficacy of treating high-risk myelodysplastic syndrome (HR-MDS) and acute myeloid leukemia (AML) patients with sabatolimab plus hypomethylating agent (HMA), prior to undergoing transplantation. Dr Brunner first highlights the concerns associated with checkpoint inhibitors and post-transplant immune-related toxicities or events such as graft versus host disease (GvHD). Dr Brunner then summarizes some of the main results of this study, which showed that severe GvHD was relatively low, and treatment with sabatolimab did not have a negative impact on post-transplant outcomes when compared to treatment with azacitidine alone. Dr Brunner concludes by mentioning the excitement around upcoming Phase II and III studies, as well as the importance of trying to optimize disease pre-transplant so that post-transplant outcomes are better. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA, 2021.
Disclosures
Janssen: Research Funding; BMS/Celgene: Consultancy, Research Funding; Takeda: Consultancy, Research Funding; Acceleron: Consultancy; Agios: Consultancy; Keros Therapeutics: Consultancy; GSK: Research Funding; Aprea: Research Funding; AstraZeneca: Research Funding; Novartis: Consultancy, Research Funding.
